Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

Molecular Tumor Board: 56-year-old male with metastatic ductal adenocarcinoma of pancreas and RET fusion

This molecular tumor board reviews tumor-agnostic biomarker testing and targeted therapy selection for RET alterations in a patient with advanced pancreatic ductal adenocarcinoma. We also provide an overview of risk factors, prognosis and biomarker-driven therapy selection underscoring the importance of comprehensive genomic profiling in patients with advanced pancreatic cancer. 

Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer

AACR Annual Meeting 2024

ACMG Annual Clinical Genetics Meeting

Annual Biomarkers Congress 2024

8th Annual Liquid Biopsy for Precision Oncology Summit

Molecular Tumor Board: 68 year-old female with Stage IV lung adenocarcinoma and EGFR and KRAS mutations on liquid biopsy

This latest molecular tumor board reviews a case of a 68 year-old female with metastatic lung adenocarcinoma with an EGFR L848R mutation. Frontline biomarker testing provided initial options for therapy, but at progression liquid biopsy testing was confounded by clonal hematopoiesis. 

Molecular Tumor Board: 33 year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer

Recognizing and mitigating cancer treatment toxicities is an essential piece of a survivorship plan after curaing cancer. Our latest molecular tumor board discusses an important intersection of cardiology and oncology in breast cancer through a case of a 33-year-old female with locally advanced ER/PR-negative, HER2-positive breast cancer.

Society for Laboratory Automation and Screening 2024